WASHINGTON, July 16, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), the global life sciences and diagnostics innovator, today published its 2024 Sustainability Report which conveys the depth and scope of Danaher's sustainability program and highlights important milestones the Company achieved during the past year."At the heart of everything we do at Danaher is our commitment to continuous improvement, and our sustainability program exemplifies this commitment," said Raine ...

Core Insights - Danaher Corporation has initiated a research collaboration with Stanford University's Department of Bioengineering to enhance cancer drug screening through advanced microscopy and AI technologies [1][2] - The collaboration aims to address the high failure rates in oncology drug trials by better understanding the tumor microenvironment and the spatial interactions of proteins within tumors [2][3] Company Overview - Danaher Corporation is a leading global innovator in life sciences and diagnostics, focusing on improving human health through advanced science and technology [4] - The company employs approximately 63,000 associates worldwide and is committed to accelerating the discovery and delivery of life-changing therapies [4] Collaboration Details - The partnership involves Leica Microsystems, a Danaher subsidiary, and aims to develop an analysis engine capable of detecting spatial, proteomic, and metabolic changes in tumors [2][3] - The research will utilize the latest findings in spatial biology and AI to screen complex cellular systems, potentially leading to more effective cancer treatments [2]

Ideally Suited for Satellite and Independent Labs, the new DxC 500i Analyzer Offers Flexibility, Scalability and Data Commutability with Extensive Chemistry and Immunoassay Assay MenuThe New DxC 500i Analyzer Incorporates Recently Introduced DxC 500 AU Chemistry Analyzer Technology with Six Sigma PerformanceBREA, Calif., July 9, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today introduces the new DxC 500i Clinical Analyzer*, an integrated clinical chemistry and immunoass ...

WASHINGTON, June 24, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2024 on Tuesday, July 23, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations.The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading " ...

WASHINGTON, June 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a leading global life sciences and diagnostics innovator, today announced that Julie Sawyer Montgomery will succeed Joakim Weidemanis as Executive Vice President, Diagnostics effective as of July 1, 2024. Mr. Weidemanis will support the transition over the next three months and will retire from Danaher on September 30, 2024 after 13 years of service.  Ms. Sawyer Montgomery, currently Vice President and Gr ...

Danaher Corporation (DHR) is posed to gain from strength in the Life Sciences segment and accretive acquisitions.However, softness in the Biotechnology segment raises concerns for the company. Decreased demand in the bioprocessing business has been weighing on the performance of the segment. Given the company’s international exposure, forex woes are weighing on its top line.What’s Aiding DHR?Business Strength: Stable demand in the academic and applied markets and strong momentum in the genomics consumables ...

Move reflects increasing investment in AI as driving force for innovation and productivity.Company will host Innovation Summit in December focused on AI in R&D.WASHINGTON, June 5, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator, today announced the creation of the new role of Chief Data & Artificial Intelligence (AI) Officer and the appointment of Dr. Martin Stumpe to the role.Jose-Carlos Gutierrez-Ramos, Senior Vice President and Chief Science Officer, Danahe ...

A month has gone by since the last earnings report for Danaher (DHR) . Shares have added about 6.7% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Danaher due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Danaher Q1 Earnings Beat, Biotechnology Sales Dip Y/YDanaher’s ...

Danaher Corporation (DHR) has been benefiting from strength in its Life Sciences segment, driven by stable demand in the academic and applied markets, and strong momentum in the genomics consumables business. The company has been witnessing positive responses from its new products like IDBS' Polar Insight and Molecular Devices' CellXpress.ai, which help accelerate the drug discovery process and bring new therapies to market faster. Also, in the Diagnostics unit, new solutions like Beckman Coulter's DxI 9000 ...

Summary of Danaher Corporation's Conference Call Company Overview - **Company**: Danaher Corporation - **Industry**: Life Sciences and Diagnostics - **Conference Date**: May 14, 2024 - **Participants**: Rainer Blair (CEO), Michael Ryskin (Bank of America) Key Points Financial Performance - Danaher reported a strong start to the year with a top line performance contraction of only 4% against guidance of high single digits, achieving operating margins of 30% and generating cash flow of $1.4 billion for the quarter [4][4][4] Bioprocessing Segment - Bioprocessing saw a decline in high teens but showed sequential improvement in order growth, with mid single-digit growth in sequential orders [5][6] - Book-to-bill ratio improved from approximately 0.8-0.85 in the previous quarter to 0.95 in Q1 [7] - Cancellation requests were minimal, indicating improved order visibility [7] - Inventory destocking is expected to be largely resolved by the end of Q2, with large pharma and CDMO customers returning to normal ordering patterns [8][9] - Long-term growth in bioprocessing is projected at high single digits, supported by increasing biologic drug penetration and diverse therapeutic modalities [13][14] Large Pharma Market - Large pharma is experiencing a growth rate of 9-10% in biologics, with a strong pace of innovation and investment [18] - The Inflation Reduction Act (IRA) is expected to favor biologic drugs with longer protection periods, potentially increasing volume-driven business for Danaher [20][21] Instrumentation Segment - Instrumentation, accounting for about 10% of total business, is undergoing normalization after a period of demand pull-forward [23] - Improvements are anticipated in the second half of the year as pharma companies resume normal operations [24] Cepheid Performance - Cepheid has significantly expanded its installed base and assay offerings, with over 30 approved assays in the U.S. and 40 internationally [29] - The long-term growth rate for Cepheid's non-respiratory business is expected to be in the low double digits, above the fleet's growth rate [34] Aldevron and Abcam Updates - Aldevron continues to grow at attractive rates, serving as a gold standard in gene editing solutions [36] - Abcam is in the early stages of integration, with expectations of high single-digit long-term growth [38] Future Outlook - Danaher is positioned to exit the pandemic stronger, with a projected revenue of $24 billion and a long-term growth rate of high single digits [41][42] - The company emphasizes a disciplined approach to M&A, focusing on smaller and medium-sized deals in the current high-interest-rate environment [48] Unique Competitive Advantage - Danaher’s competitive advantage lies in its unique combination of leading assets, a strong operational framework (Danaher Business System), and a disciplined approach to capital allocation [54][55] Additional Insights - The company has transformed its portfolio significantly since 2018, replacing over $7 billion in revenue through strategic acquisitions [41][42] - The focus on cash flow generation and operational efficiency is highlighted as a key differentiator in the life sciences sector [55]